204 related articles for article (PubMed ID: 32833021)
41. Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods.
Watson M; Saraiya M; Ahmed F; Cardinez CJ; Reichman ME; Weir HK; Richards TB
Cancer; 2008 Nov; 113(10 Suppl):2841-54. PubMed ID: 18980203
[TBL] [Abstract][Full Text] [Related]
42. The Role of Nursing in Preventing HPV-Related Cancers.
Baldwin CM
Clin J Oncol Nurs; 2020 Oct; 24(5):471. PubMed ID: 32945790
[TBL] [Abstract][Full Text] [Related]
43. Rural-Urban Differences in Human Papillomavirus-associated Cancer Trends and Rates.
Zahnd WE; Rodriguez C; Jenkins WD
J Rural Health; 2019 Mar; 35(2):208-215. PubMed ID: 29808500
[TBL] [Abstract][Full Text] [Related]
44. The Human Papillomavirus as a Common Pathogen in Oropharyngeal, Anal and Cervical Cancers.
Otter S; Whitaker S; Chatterjee J; Stewart A
Clin Oncol (R Coll Radiol); 2019 Feb; 31(2):81-90. PubMed ID: 30385006
[TBL] [Abstract][Full Text] [Related]
45. Distribution of Vaccine-Type Human Papillomavirus Does Not Differ by Race or Ethnicity Among Unvaccinated Young Women.
Whittemore D; Ding L; Widdice LE; Brown DA; Bernstein DI; Franco EL; Kahn JA
J Womens Health (Larchmt); 2016 Nov; 25(11):1153-1158. PubMed ID: 27754751
[TBL] [Abstract][Full Text] [Related]
46. Trends in Human Papillomavirus-Associated Cancers - United States, 1999-2015.
Van Dyne EA; Henley SJ; Saraiya M; Thomas CC; Markowitz LE; Benard VB
MMWR Morb Mortal Wkly Rep; 2018 Aug; 67(33):918-924. PubMed ID: 30138307
[TBL] [Abstract][Full Text] [Related]
47. Incidence and risk factors for HPV-associated cancers in women with end-stage renal disease.
Han J; Waller JL; Colombo RE; Spearman V; Young L; Kheda MF; Mohammed A; Bollag WB; Nahman NS; Baer SL
J Investig Med; 2020 Jun; 68(5):1002-1010. PubMed ID: 32503931
[TBL] [Abstract][Full Text] [Related]
48. The burden of HPV associated cancers in two regions in Nigeria 2012-2014.
Jedy-Agba EE; Dareng EO; Adebamowo SN; Odutola M; Oga EA; Igbinoba F; Otu T; Ezeome E; Bray F; Hassan R; Adebamowo CA
Cancer Epidemiol; 2016 Dec; 45():91-97. PubMed ID: 27780076
[TBL] [Abstract][Full Text] [Related]
49. Prognostic and Predictive Clinical and Biological Factors in HPV Malignancies.
Sud S; Weiner AA; Wang AZ; Gupta GP; Shen CJ
Semin Radiat Oncol; 2021 Oct; 31(4):309-323. PubMed ID: 34455986
[TBL] [Abstract][Full Text] [Related]
50. Comprehensive control of human papillomavirus infections and related diseases.
Bosch FX; Broker TR; Forman D; Moscicki AB; Gillison ML; Doorbar J; Stern PL; Stanley M; Arbyn M; Poljak M; Cuzick J; Castle PE; Schiller JT; Markowitz LE; Fisher WA; Canfell K; Denny LA; Franco EL; Steben M; Kane MA; Schiffman M; Meijer CJ; Sankaranarayanan R; Castellsagué X; Kim JJ; Brotons M; Alemany L; Albero G; Diaz M; de Sanjosé S;
Vaccine; 2013 Dec; 31 Suppl 5():F1-31. PubMed ID: 24331745
[TBL] [Abstract][Full Text] [Related]
51. Variation in genital human papillomavirus infection prevalence and vaccination coverage among men and women in the USA.
Han JJ; Tarney CM; Song J
Future Oncol; 2017 Jun; 13(13):1129-1132. PubMed ID: 28589730
[TBL] [Abstract][Full Text] [Related]
52. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan.
Tay SK; Ngan HY; Chu TY; Cheung AN; Tay EH
Vaccine; 2008 Aug; 26 Suppl 12():M60-70. PubMed ID: 18945415
[TBL] [Abstract][Full Text] [Related]
53. Harnessing the power of prevention: human papillomavirus vaccines.
Mayeaux EJ
Curr Opin Obstet Gynecol; 2006 Feb; 18 Suppl 1():s15-21. PubMed ID: 16520680
[TBL] [Abstract][Full Text] [Related]
54. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies.
Tota JE; Chevarie-Davis M; Richardson LA; Devries M; Franco EL
Prev Med; 2011 Oct; 53 Suppl 1():S12-21. PubMed ID: 21962466
[TBL] [Abstract][Full Text] [Related]
55. Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study.
Dondog B; Clifford GM; Vaccarella S; Waterboer T; Unurjargal D; Avirmed D; Enkhtuya S; Kommoss F; Wentzensen N; Snijders PJ; Meijer CJ; Franceschi S; Pawlita M
Cancer Epidemiol Biomarkers Prev; 2008 Jul; 17(7):1731-8. PubMed ID: 18628425
[TBL] [Abstract][Full Text] [Related]
56. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
57. Risk Behaviors Correlate with Higher Prevalence of Papanicolaou, Human Papillomavirus, and Human Immunodeficiency Virus Screening Among Women in the United States.
Merrill RM; Williams EN; Fuhriman H
J Womens Health (Larchmt); 2021 Apr; 30(4):615-624. PubMed ID: 33085563
[No Abstract] [Full Text] [Related]
58. Human papillomavirus-associated cancers - United States, 2004-2008.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Apr; 61():258-61. PubMed ID: 22513527
[TBL] [Abstract][Full Text] [Related]
59. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
60. Differences in Sociodemographic Correlates of Human Papillomavirus-Associated Cancer Survival in the United States.
Osazuwa-Peters N; Simpson MC; Rohde RL; Challapalli SD; Massa ST; Adjei Boakye E
Cancer Control; 2021; 28():10732748211041894. PubMed ID: 34696619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
